

Index

Note: page numbers for figures are in *italics*, tables in **bold**.

- abatacept 148, 202
ABO compatibility
 blood transfusion 310
 transplantation 158, 159, 167
ABVD chemotherapy regimen 129–30
accessory molecules 10–11
acetylcholine receptor (AChR) antibodies 318, 319, 341–2, **342**
acquired immune deficiency syndrome (AIDS)
 see HIV infection/AIDS
activation-induced cell death (AICD) 113
activation-induced cytidine deaminase (AID)
 12
 deficiency 62
active immunity 149, *149*
acute allograft rejection 161, 161–2
acute idiopathic polyneuritis *see* Guillain–Barré syndrome
acute lymphoblastic leukaemia (ALL) 123–6
 age of onset 123, *124*
 B-cell (B-ALL) 123, 124
 cell surface markers 123, *125*
 complications 124, **126**
 diagnosis 123, **125**, *346*
 T-cell (T-ALL) 123, 124
 treatment 126, 169–70
acute myeloid leukaemia (AML) 167
acute nephritis 172
acute-phase proteins 30
acute-phase responses 70
acute renal failure 172
acute tubular necrosis 159
adalimumab **145**, 204, 206
adaptive immune response 2, **3**, 24–8
 combined primary deficiencies 66–70
 effector molecules **11**
 molecules recognized 4
 recognition molecules 6–10
 T-cell mediated 24–7
Addison's disease **116**, **297**, 297–8
adefovir 280–1
adenosine deaminase (ADA) deficiency 66, 67–8, **68**, 69
adenovirus 238
adhesion molecules **15**, 15–16
 immunoglobulin supergene family 10–11, *11*
 leucocyte–endothelial interactions 15–16, *16*
adjuvants 4, 150–1
adrenal antibodies **340**
adrenal disease 297–8
adult T-cell leukaemia/lymphoma (ATL) 128
affinity maturation 28
agammaglobulinaemia 56
 X-linked (XLA) 58–9
AIRE gene mutations 49, 108, **110**, 116, 298
Aire protein 111
airways
 defence mechanisms 246, 247
 hyper-responsiveness, asthma 96
inflammation, asthma 96, 96
 remodelling, chronic asthma 96
albuminuria, overt 172
alcohol-induced liver disease 287
alemtuzumab (Campath-1H) 114, 127, **144**, 160
alkylating agents 139–40
allergen-specific immunotherapy 90, 92, 93–4
allergic bronchopulmonary aspergillosis 50, 253–4
allergic conjunctivitis 92–3, **238**, 239, 240
allergic contact dermatitis *see* contact dermatitis
allergic rhinitis 93–4, *94*
allergy 86–104
 definition 87
 food *see* food allergy
 genetic susceptibility 88–9, **89**
 hygiene hypothesis 52, 89
 laboratory tests 342–4
 respiratory 93–7
 risk factors 87
 skin disease 100–4
alloantibodies
 causing anaemia 305
 causing thrombocytopenia 306
allogeneic grafting 158
allorecognition 163
alopecia areata 228
 $\alpha\beta$ T cells 6, 24–5, 31–3
aluminium compounds (alums) 151
alveolar macrophages 246
amenorrhoea, primary 298
amyloid A protein (AA) 190
amyloidosis 189–90, **190**
 acute phase-associated (AA) 190
 light chain-associated (AL) 136, 189–90, 191
 treatment 190, **191**
anaemia *300*
 alloantibodies causing 305
 aplastic 169, 308–9
 haemolytic *see* haemolytic anaemia
 pernicious *see* pernicious anaemia
anakinra 206
anaphylactoid reactions 88, 90–2
anaphylaxis 87, 89–90, **90**
 cases 91
 food-related, exercise-induced 90
 systemic 89–90
anaphylotoxins 22
ANCA *see* antineutrophil cytoplasmic antibodies
anergy 113, 114
angioedema 100, **101**, 104
 hereditary (HAE) 228–9, 229
ankylosing spondylitis **115**, 202, 203
antibodies 2, 11–12
 see also autoantibodies; immunoglobulins
 affinity maturation 28
 deficiencies 37
 detection methods 339
direct functions 28
indirect functions 28–9
monoclonal *see* monoclonal antibodies
polyclonal 141–2, **334**, 335
precipitating 344, 344
primary deficiencies 55–66
primary response 27, 27
production 27–8
secondary deficiencies 65
secondary response 27, 27, 28
antibody-dependent cell-mediated cytotoxicity (ADCC) 22–3
antibody-dependent enhancement of infection (ADEI) 42
anticardiolipin antibodies *see* antiphospholipid antibodies
anti-CD3 antibodies **145**
anti-CD4 antibodies **145**
anti-CD20 antibodies **145**
anti-CD28 humanized monoclonal antibody 147
anti-CD40L antibodies **145**
anticentromere antibodies 233, **340**
anti-cyclic citrullinated peptide (CCP) antibodies 197, 200
antigen(s) 4
 diversity of binding 10
 endogenous/viral 7–8, 8
 exogenous 8, 8
 immunogenicity 4
 MHC-restricted recognition 7, 7
 processing 7–8, 8, 24
 recognition by T cells 6–8, 7, 25
 recognition molecules 6–10
 thymus-dependent (T-dependent) 4, 42
 thymus-independent (T-independent) 4, 28, 42–3
antigenic disguise 52–3
antigenic drift 41
antigenic modulation 51
antigenic shift 41
antigenic variation 41, 44, 51
antigen presentation 7–8, 8
 accessory molecules 10–11, *11*
 co-stimulatory molecules 19, *19*
antigen-presenting cells (APCs) 18
antigen-specific IgE antibodies 343
anti-glomerular basement membrane (anti-GBM) disease 184, 184–5, 185
anti-HIV antibodies 82
antilymphocyte globulin 308–9
antimitochondrial antibodies (AMAs) 284–5, 285
 detection *334*, **340**, *342*
antineutrophil cytoplasmic antibodies (ANCA)
 -associated glomerulonephritis 184, 185–6, 187
 cytoplasmic (cANCA) 185
 detection **340**, *342*
 granulomatosis with polyangiitis (GPA) 259

- inflammatory bowel disease 275
 perinuclear (pANCA) 185
 vasculitis associated with 185–6, 187, 230
- antinuclear antibodies (ANA)
 detection 334, 340, 340–1, 341
 mixed connective tissue disease 213
 rheumatoid arthritis 197
 SLE 207, 208
- antiphospholipid antibodies 309
 detection 342
 recurrent spontaneous abortion 328–9
 SLE 206, 207, 208, 309
- antiphospholipid antibody syndrome, primary 309, 309
- antiplatelet antibodies 307, 330
- antiretroviral therapy 82–4
- antistreptococcal deoxyribonuclease B (anti-DNase B) titre 43
- antistreptolysin O (ASO) titre 43
- anti-thymocyte globulin (ATG) 144
- anti-tumour necrosis factor (anti-TNF) agents *see* tumour necrosis factor (TNF) inhibitors
- aortitis 261–2
- APECED (autoimmune polyendocrinopathy, candidiasis and ectodermal dysplasia) 108, 116, 298
- aplastic anaemia 169, 308–9
- apoptosis
 B cell 114
 defects, SLE pathogenesis 211–12
 T cell 112, 113
- Artemis deficiency 68
- arthritis
 chronic childhood 205, 205–6
 enteropathic 204
 immune-mediated 197
 infection and 195–7
 inflammatory 195
 psoriatic 204
 reactive (urethritis) 197, 202, 203–4, 241
 rheumatoid *see* rheumatoid arthritis
 septic 196, 196–7
 viral 197
- Arthus reaction 30
- aspergillosis, allergic bronchopulmonary 50, 253–4
- Aspergillus fumigatus 49, 50, 253
- asthma 94–7
 allergic 94–6, 95
 diagnosis 96
 familial 94
 genetic susceptibility 88–9, 89, 94
 idiopathic 95
 pathogenesis 94–6, 96
 precipitating factors 95, 96–7
 treatment 97
- ataxia telangiectasia 69
- atherosclerosis 210, 261
- atizumab 146
- atopic eczema (atopic dermatitis) 102, 102–4, 224
 genetic susceptibility 88–9, 89, 102
 pathogenesis 102, 103
- atopic keratoconjunctivitis 238
- atopy 87, 88–9, 89
- autoantibodies
 detection methods 339–42
 endocrine diseases 289, 289–90
 mechanisms of prevention 113–14
 mechanisms of tissue damage 118–19
 placental transfer 107
 secondary 30
- type II hypersensitivity 30, 32
 virus-induced production 42
 autoantigens (self-antigens) 4
 causing disease 109
 peripheral T-cell tolerance 111–12
 rheumatoid arthritis 200, 200
- autoimmune disease
 definition 106, 107
 environmental factors 116–18
 genetic factors 109, 110, 115, 115–16
 intravenous immunoglobulin (IVIG) 142, 142
 mechanisms of tissue damage 118–19, 119
 non-organ-specific 106–7
 organ-specific *see* organ-specific autoimmune diseases
 patterns 106–8
 placental transfer 106, 107
 primary antibody deficiencies 65
 risk factors 108–9
 self-antigens causing 109
 skin 225–8
 treatment 119–20
 virus-induced 42
- autoimmune enteropathy 65, 274–5
- autoimmune haemolytic anaemias (AIHA)
 300–5, 301
 causes 303
 cold antibody 301, 304
 drug-induced 304–5
 pregnancy and 330
 warm antibody 301, 301–4
- autoimmune hepatitis 283–4, 284
- autoimmune polyendocrine disease 298–9, 299
- autoimmune polyendocrinopathy, candidiasis and ectodermal dysplasia (APECED) 108, 116, 298
- autoimmunity 105–20
 breakdown of tolerance and 114–15
 definition 106
 factors triggering 115–18
 mechanisms preventing 109–14
- autoinflammatory syndromes 217–18, 218
- autologous grafting 158
- autophagy 112, 113
- autoreactive T cells 30
 deletion in thymus 31, 109–11, 111
 peripheral mechanisms of tolerance 111–13, 112
- Avastin (bevacizumab) 147
- azathioprine 139
- B7-1 (CD80) 19, 19
- B7-2 (CD86) 19, 19
- bacille Calmette–Guérin (BCG) vaccine 46, 48, 251
 combined primary T- and B-cell immunodeficiencies 67
 routine immunization 151, 151
- bacteria
 antigens 42–3
 evasion of immune defences 43–4, 44
 extracellular 37
 intracellular 37
 as superantigens 43, 43
- bacterial infections 42–5
 bystander damage 44–5, 46
 conjunctiva 238
 normal immune responses 42–3
 respiratory tract 247
 specific immune responses 37, 37
- bagassosis 255
- bamboo spine 203
- bare lymphocyte syndrome 68
- basement membrane zone (BMZ) antibodies 227
- basiliximab 146, 160
- basophil activation test (BAT) 343
- B-cell receptors (BCRs) 8–10, 27
 receptor editing 114
 VDJ gene recombination 10, 10
- B cells 2
 absent mature circulating 56, 58–9
 adaptive immune response 24, 27–8
 antibody production 27–8
 as antigen-presenting cells 18, 20
 antigen recognition molecules 8–10
 development 3, 33, 60
 EBV-induced transformation 38
 effector molecules 11–12
 mucosal immune system 264
 quantification methods 345
 recirculation pathways 33, 33
 rheumatoid arthritis 199, 199–200
 tolerance, mechanisms 113–14
- Bcl-2 deficiency 110
- BCR-ABL fusion protein 123, 124
- Behcet's disease 204–5, 241
- belatacept 148
- belimumab 207–9
- Bence Jones proteins 135, 337
- Berger's disease *see* IgA nephropathy
- berylliosis 252
- β_1 integrins 15, 16
- β_2 -adrenoceptor agonists 97
- β_2 integrins 15, 16, 346
- β_3 integrins 15, 16
- bevacizumab (Avastin) 147
- biodegradable polymers 151
- biopsy material
 immunofluorescence 339–40
 immunohistochemistry 342
- bird fancier's lung 255, 256
- BK polyoma virus 164
- blood-borne infections 310–11
- blood-brain barrier 312
- blood-eye barrier 237
- blood transfusion 310–11
 combined primary T- and B-cell immunodeficiencies 67
 complications 310, 310
 transmission of infections 310–11, 311
- B lymphocytes *see* B cells
- bone lesions, multiple myeloma 134, 135
- bone marrow 30–1, 33
 ablation prior to stem cell transplant 148, 167
 multiple myeloma 134, 135
- bone marrow transplantation 167, 168
see also haematopoietic stem cell transplantation
 HLA matching 158
- Borrelia burgdorferi 196
- Borrelia recurrentis 44
- bortezomib 135
- breast cancer 156
- breastfeeding 327
- bronchial-associated lymphoid tissue (BALT) 246
- bronchial hyper-responsiveness, asthma 96
- bronchiectasis 60
- bronchoalveolar lavage (BAL) 246
- bronchodilators 97
- Bruton's disease *see* X-linked agammaglobulinaemia

- Bruton's tyrosine kinase (Btk) 59
Btk gene mutation 59
 bullous pemphigoid 227, 227
 bullous skin diseases 225–7, 226
 α -bungarotoxin 341–2
 Burkitt's lymphoma 38, 40
 Burnet's clonal selection theory 25, 28
 burns, allogeneic skin grafting 166
 bystander damage 42, 44–5, 50, 53
- C1 inhibitor (C1-INH) 16, 229
 deficiency 76, 228–9, 229
 replacement therapy 229
- C1q 21–2
 deficiency 75, 211
- C3 21
 assays 337, 338, 338
 deficiency 75
 serum, kidney disease 178, 182
- C3a 22
- C3b 22, 29
- C3 convertases 21, 22
- C3 nephritic factor (C3 NeF) 182–3, 338
- C4 assays 337, 338, 338
- C5a 22
- C5 convertase 22
- C5 deficiency 76
- C6 deficiency 76
- C7 deficiency 76
- calcineurin inhibitors 140–1
 renal transplant recipients 160
 topical 103–4
- calprotectin 277
- Campath-1H (alemtuzumab) 114, 127, 144, 160
- Campobacter jejuni infection 118, 320
- cancer
see also malignant disease
 immunosurveillance 155
 immunotherapy 155–6
- Candida albicans infections (candidiasis) 49, 49–50
 chronic mucocutaneous (CMC) 49, 69
 superficial 49
- capsules, bacterial 44
see also polysaccharide capsular antigens
- CARD9 gene polymorphism 50
- cardiac allograft vasculopathy (CAV) 166
- cardiac disease 259–61, 260
- cat allergens 96–7
- CATCH 22 syndrome (Di George anomaly) 66, 69
- CD1 5, 27
- CD3 6, 6
 activation failure 68
 δ chain defect 68
- CD4⁺ CD25⁺ T cells 26, 27
- CD4⁺ counts, HIV infection 79, 82, 83
- CD4⁺ T cells 24–5
 antigen presentation to 8, 8
 effector subtypes 25–6
 graft rejection 162–3
 HIV infection 82
 rheumatoid arthritis 199, 199
- CD8⁺ T cells 25
 antigen presentation to 7–8, 8
 effector functions 26
- CD14 36
- CD18/CD11 proteins 15, 36, 346
- CD28 19, 19
- CD40 27, 27–8
- CD40 ligand (CD40L) 27, 27–8
 deficiency 60, 61, 61, 62
- CD59 (protectin) 16
- CD80 (B7-1) 19, 19
- CD86 (B7-2) 19, 19
- CD103 (HML-1) 264
- cell-mediated immunity 2, 24–7
 impaired 37
 to infection 37
 primary deficiencies 66–70
- central nervous system (CNS)
 demyelinating diseases 314–18
 infections 313–14
- cephalosporin-induced haemolytic anaemia 304
- cerebellar degeneration 322
- cerebral malaria 50
- cerebrospinal fluid (CSF) investigations
 IgG index 337, 337
 multiple sclerosis 315, 315, 316
 oligoclonal bands 337, 337
- CH₅₀ assay 338–9
- Chagas' disease 260
- Chediak–Higashi syndrome 74, 74
- chemokine receptors 14–15
- chemokines 12–13, 14
- chemotaxis 346–7
- chemotherapy
 leukaemia 126–7
 lymphoma 129–30, 131
 multiple myeloma 135
 Waldenström's macroglobulinaemia 136
- chest diseases 245–62
- children
see also infants; neonates
 atopic eczema 102, 102
 chronic arthritis 205, 205–6
 food intolerance 98
 immune thrombocytopenia (ITP) 305–6, 307, 307
- immunization 151, 151–2
 primary antibody deficiencies 55, 57
 renal transplantation 160
 respiratory tract infections 247
- Chlamydia trachomatis 238
- chlorambucil 140
- choroiditis (posterior uveitis) 239, 243
- chorioretinitis, acute 243
- chronic active hepatitis (CAH) 283–4, 284
 hepatitis B 280
 primary biliary cirrhosis with 286
- chronic allograft nephropathy 162, 162
- chronic fatigue syndrome (CFS) 42
- chronic granulomatous disease (CGD) 72–4, 74
 autoimmune disease 110
 diagnosis 72, 75
 treatment 74, 153
- chronic inflammatory demyelinating polyneuropathy (CIDP) 321
- chronic lymphocytic leukaemia (CLL) 126–7
 age of onset 124, 126
 immunophenotyping 128
 susceptibility to infection 77, 248
- chronic mucocutaneous candidiasis (CMC) 49, 69
- chronic persistent hepatitis 280, 283
- chronic renal failure 172, 193
see also end-stage renal failure
- Churg–Strauss syndrome (CSS) 259
- cicatrizing conjunctivitis 238
- cyclosporin 140–1
 allergic disease 97, 103
 aplastic anaemia 309
- mechanism of action 140, 141
 side-effects 141
 transplant recipients 160
- citrullinated proteins (CCP) 200, 200
- classes, immunoglobulin *see* isotypes, immunoglobulin
- clonal expansion 28
- clonal selection theory 25, 28
- clones, malignant cells 122
- coagulation, immune disorders of 309–10
- cobicistat 83
- Coccidioides immitis 49
- coeliac disease 271–4, 274
 clinical presentation 273, 274
 dermatitis herpetiformis 227, 274
 histological features 271, 273
 pathogenesis 100, 271, 274
 type 1 diabetes association 299
- cold agglutinins 304
- cold antibody haemolytic anaemias 301, 304
- cold haemagglutinin disease (CHAD) 304
- cold sores (herpes labialis) 220, 221
- collagen
 type II 200, 200
 type IV α 3 chain 184
 type VII 226, 227
- colony-stimulating factors, haematopoietic 14, 154, 154
- combination antiretroviral therapy (cART) 83
- combined immunodeficiency, late-onset 62
- combined primary T- and B-cell immunodeficiencies 66–70, 69
- common cold 247
- common variable immunodeficiency (CVID) 62, 63, 65
- complement 20–2
 activation 21–2
 alternative pathway 22, 22
 breakdown products 338
 classical pathway 21–2, 22
 deficiency 75–6
 disorders, investigation 337–9
 final lytic pathway 22
 functional assays 338–9
 functions 20–1, 21
 regulation 16, 22, 23
 role in inflammation 21, 29
- complement components 20
 assays 337–8, 338
 inherited deficiencies 75, 75–6, 110, 211
 interpreting test results 338, 338
 MHC class III region 7, 8
 principles of cleavage 20, 20
 recognition of damaging material 10
- complement receptor 1 (CR1) 16, 21
- complement receptors 15, 36
- concomitant immunity 53
- conjugate vaccines 150
- conjunctivitis 238, 238–41, 239
 allergic 92–3, 238, 239, 240
 autoimmune 239
 infectious 238–9, 240
- connective tissue diseases 106–7, 195, 212–13
 lung disease 258, 258
- constant (C) region, immunoglobulin 8, 9
- contact dermatitis 104, 221–4
 agents inducing 223
 pathogenesis 222, 223
- contact dermatoconjunctivitis 238, 240
- Coombs' test 300–1, 301
 direct 302, 303
 indirect 302, 303

Copolymer 1 317
 corneal grafting 166, 241
 corneal melting syndrome, peripheral 241
 coronary artery disease 260–1
 corticosteroids 138–9
 bullous skin diseases 226
 giant cell arteritis/polymyalgia rheumatica 216
 immune system effects 138, **138**
 immune thrombocytopenia 307
 inhaled 97
 minimal-change nephropathy 187
 multiple sclerosis 317
 polyarteritis nodosa 214, 215
 side-effects 139, 139
 SLE 207
 topical 103
 transplant recipients 160
 co-stimulatory molecules 19, 19
 development of autoimmunity 115, 117
 T-cell anergy or apoptosis 113
 countercurrent immunolectrophoresis (CIE) 342, 343
 cow's milk allergy 98, 99, 104
 C-reactive protein (CRP) 30, 197
 crescentic glomerulonephritis 184, 186
 CREST syndrome 232, 233
 Crohn's disease **275**, 275–7
 arthritis 204
 histological features 275, 275
 management 276, 276–7
 pathogenesis 275–6, 276
 cryoglobulinaemia 231
 cryoglobulins 231, 336
 cryopyrin 217, **218**
 cryptic epitopes 114
 Cryptococcus neoformans **49**
 cryptogenic fibrosing alveolitis *see* idiopathic pulmonary fibrosis
 cryptogenic organizing pneumonia **257**
 cryptosporidia 267
 CTLA-4 19, 19, 113
 deficiency **110**
 cutaneous lymphocyte-associated antigen (CLA) 220
 CXCL8 (interleukin-8) **13**, **14**
 cyclic citrullinated peptide (CCP) antibodies 197, 200
 cyclophosphamide 127, 139–40
 cystic fibrosis 55, 248
 cytokine(s) 12–13, **13**–**14**
 immunosuppressive 114
 inflammatory **13**, 29, 30
 receptors 13–14
 rheumatoid arthritis pathogenesis 199, 199
 storm 147
 therapy 153–4
 cytolytic molecules 13
 cytomegalovirus (CMV) **39**
 chorioretinitis 243
 immune evasion mechanisms 41, **41**
 post-transplant infections 164, 166, 169, 169
 cytotoxic antibodies
 renal allograft rejection 161, 163
 renal transplantation 159, 160
 cytotoxic T cells (CTL/Tc) **24**
 antigen recognition 6
 effector functions 26
 daclizumab **146**, 160, 317
 danazol 229
 decay accelerating factor (DAF) **16**

Dectin1 polymorphism 50
 delayed-type hypersensitivity (type IV hypersensitivity) **30**, **32**
 contact dermatitis 221, 222, 223
 effector T cells 26
 parasite infections 53
 demyelinating diseases, central nervous system 314–18
 dendritic cells 18–20
 antigen processing 24
 classical 18
 functional defects 70–1
 functions 18–19
 immature 5, 18
 mature myeloid 5, 19
 myeloid (monocyte-derived) 18, 19
 recognition molecules 4
 surface proteins 5
 Toll-like receptor signalling 5, 5
 dengue virus 42
 dense-deposit disease (type II MPGN) **181**, 182–3
 densitometry 335, 336
 de Quervain's thyroiditis 293
 dermatitis herpetiformis 226, 227, 274
 dermatomyositis 217
 dermis 220
 desmoglein 3 antibodies 226
 desmosomes 226
 diabetes mellitus 294–7
 classification 294, **294**
 complications 296
 non-insulin-dependent (NIDDM or type 2) 294, **294**, 296
 role of immunological tests 296–7, 297
 treatment 296
 type 1 *see* insulin-dependent diabetes mellitus
 diabetic retinopathy 296
 Di George anomaly 66, **69**
 dihydrorhodamine reduction test (DHR) 74, 347
 dilated cardiomyopathy 260
 direct immunofluorescence 339
 renal biopsies 180, **181**
 skin biopsies 225–6, 226, 227, 232
 discoid lupus erythematosus (DLE) **110**, 231–2, **233**
 disease-modifying anti-rheumatic drugs (DMARDs) 202
 DNA analysis 347–9
 DNA hybridization 347–8
 DNA microarrays 349–50
 dog allergens 96–7
 double-stranded DNA (dsDNA)
 antibodies (anti-dsDNA) 207, **208**, 341, **342**
 pathogenic role 210
 small molecule inhibitors 209
 Dressler's syndrome 260
 drug allergy (hypersensitivity) 90, 92, 117, 287, 287
 drug-induced haemolytic anaemia 304–5
 drug-induced liver disease 287
 drug-induced lupus 117, 119, 207
 drug-induced neutropenia 308
 drug-induced thrombocytopenia 308
 drug-induced tubulointerstitial nephritis, acute 191–2
 drugs, triggering autoimmunity 117–18, **118**
 dry eyes 213, 214, 241
 dry mouth 213
 EBV *see* Epstein–Barr virus
 eculizumab **146**, 183, 305
 efavirenz 83
 effector molecules, immune 11–13
 receptors for 13–15
 effector phase, immune response 2
 elimination diet 100
 emtricitabine 83
 encephalitis 313
 parainfectious 314
 endocarditis 260
 endocrine diseases 288–99
 mechanisms of autoimmune 289, 289–90
 endomysial antibodies 273, **340**
 endothelial cells 17
 glomerular 173, 173
 leucocyte interactions 15–16, **16**
 endotoxin 4
 end-stage renal failure (ESRF)
 causes 193, **193**
 IgA nephropathy 175
 renal transplantation 158
 SLE 183
 enfuvirtide 83
 entecavir 280–1
 enteropathic arthritis 204
 enterovirus infections, chronic 65
 enthesis-related arthritis (ERA) 205, 206
 enzyme-linked immunosorbent assay (ELISA) 339, 341, 341–2, **342**
 eosinophilia
 helminth infections 52
 pneumonic 254
 pulmonary 253–4, 254
 eosinophilic pneumonia, idiopathic 254, 254
 eosinophils, asthma 96
 eotaxin **14**
 epidermis 220
 epidermolysis bullosa acquisita (EBA) 227
 epinephrine (adrenaline) 90
 episcleritis 241
 epithelial cells
 asthma pathogenesis 95
 glomerular 173, 173–4
 epitopes 4
 cryptic 114
 shared 200, **200**
 spreading 114–15, **115**
 epratuzumab 209
 Epstein–Barr virus (EBV) 37–8, **39**
 antigens, antibody responses 37, 37–8
 inducing autoimmune disease 42
 malignant disease and 38, **40**, 128, 141
 reactivation 38
 erythema nodosum 45, 230, 251
 erythema nodosum leprosum (ENL) 48
 E-selectin **15**
 etanercept 148, 202, 206
 etaracizumab **146**
 evolution 2
 exophthalmos, thyroid disease 291–2
 experimental allergic encephalomyelitis (EAE) 316
 experimental allergic uveitis (EAU) 242
 extracorporeal photochemotherapy 148
 extractable nuclear antigen (ENA) antibodies 207, **208**, 342, **343**
 extrinsic allergic alveolitis (EAA) 254–6, **255**
 eye
 anatomy 238
 immune defences 237
 eye diseases 236–44
 symptoms and signs 239
 systemic diseases causing **239**
 thyroid 291–2

Factor B, assays 338, **338**
 Factor H **16**
 deficiency 75
 Factor I **16**
 factor VIII antibodies 309
 familial cold autoinflammatory syndrome **218**
 familial Mediterranean fever (FMF) 217, 218, **218**
 farmers' lung 50, **255**
 Fas 237
 deficiency **110**, 211
 Fas ligand (FASL) 113, 237
 Fc γ RIII receptors 23, 28
 Fc receptors (FcR) 15, 36
 FcRn receptor 11, 15
 IgG homeostasis 142, 142
 placental tissues 325
 feather pluckers' disease **255**
 Felty's syndrome 308
 fetus 325
 diseases due to alloimmunization 329–30
 immune responsiveness 325, 326
 protection against infection 325–8
 fibrosis, in autoimmune disease 119
 filaggrin mutations 102
 fingolimod 317
 flow cytometry 345, 345, 346, 347
 fludarabine 127
 fluorenzyme immunoassay (FEIA) 343
 focal glomerulosclerosis 188
 follicular dendritic cells 18, 19, 20
 food allergic disease 98
 food allergy 97–100, 103, 270–1
 food challenge 100
 food fads and aversions 98, **98**
 food intolerance 98, **98**
 atopic eczema and 102
 clinical spectrum 98
 diagnosis 100
 differential diagnosis in children **98**
 foods, adverse reactions to 98, **98**, 100
 FOXP3 gene 26, 27, **110**, 116
 Freund's complete adjuvant 150–1
 fungal infections 48–50, **49**
 bystander damage 50
 mechanisms of immunity 48–50
 recurrent 37
 fusion proteins, for blocking receptors 148
 gamma-delta T cells ($\gamma\delta$ T cells) 6, 25, 264–5
 ganglioside antibodies 320, 322
 gastric parietal cell (GPC) antibodies 268, 268–70, **270**, **340**
 gastritis 268–70
 atrophic 268–70, 269
 types 268, **269**
 gastrointestinal disease 263–77, **267**
 autoimmune enteropathy 274–5
 food-induced 270–4
 infections 267–8
 primary antibody deficiencies 65
 gastrointestinal tract
 immune mechanisms 264–5, 266
 spectrum of immune response 265
 GB virus 283
 gender differences
 autoimmune diseases 108–9, 116
 SLE 212
 gene expression chips 349–50
 gene mutations, cancer development 122
 gene rearrangement studies 349

gene therapy 154–5
 prerequisites **70**, 154
 SCID 68–70, 154, **155**
 genetic disease, diagnosis 349
 genomics 349–50
 giant cell arteritis (GCA) 215, 215–16, 216
 glomerular basement membrane (GBM) 173, **173**
 antibodies 184, 185, **342**
 glomerulonephritis 172, **173**, 173–4
 acute 176–8
 chronic 178–83
 classifications 173–4, **174**
 crescentic 184, 186
 mechanisms 172, 174, **175**
 membranoproliferative (MPGN) 180–3
 membranous 188–9
 post-infectious 177–8
 post-streptococcal (PSGN) 45, 45, 177–8, 178, 179
 rapidly progressive (RPGN) 184, 184–6
 recurrence in grafted kidneys 165, 193, **193**
 glomerulosclerosis, focal 188
 glomerulus, structure 173, **173**
 glutamic acid decarboxylase (GAD) antibodies 295, 320
 gluten 271
 gluten-sensitive enteropathy *see* coeliac disease
 gonadal disease, autoimmune 298
 gonococcal infections
 recurrent 76
 septic arthritis 196
 Goodpasture's syndrome 184, 259
 GPI anchor protein, abnormal 305
 graft rejection
 acute 161, 161–2
 chronic 260
 chronic allograft nephropathy 162, 162
 hyperacute 161
 immunopathology 162, 162–3
 graft-versus-host disease (GvHD) 126, 166, 168–9
 graft-versus-leukaemia effect 169
 granulocyte colony-stimulating factor (G-CSF) **14**, 154, **154**
 transplant recipients 167, 169
 granulocyte macrophage colony-stimulating factor (GM-CSF) **14**, 154, **154**
 transplant recipients 167, 169
 granulomas 248–50, 249
 sarcoid 252
 tuberculous 250
 vasculitis with 230, **231**
 granulomatosis with polyangiitis (GPA) 215, 259, 259
 histological features 215
 joint involvement 216–17
 pathogenesis 230
 renal involvement 185
 granulomatous lung diseases 248–52, 249
 granzymes 13
 Graves' disease 114, 290–2, 291
 neonatal 291, 330
 great vessels, diseases of 260, 261–2
 Group A β -haemolytic streptococcal infections 43, 44–5
 Guillain–Barré syndrome (GBS) 118, 320–1
 gut *see* gastrointestinal tract
 gut-associated lymphoid tissue (GALT) 264–5, 266
 haematological diseases 300–11
 haematopoietic cells, malignant transformation 122, 123, **124**

haematopoietic progenitor cells, reduced numbers 308–9
 haematopoietic stem cell transplantation (HSCT) 166–70
 allogeneic 167, 168–9
 aplastic anaemia 309
 autologous 170
 bone marrow ablation prior to 148, 167
 complications 168–9
 hyper-IgM syndrome 61
 immune reconstitution after 167–8, 168
 indications and patient selection 167, **167**
 leukaemia 126, 167, **169**, 169–70
 lymphoma 131
 multiple myeloma 135
 results 169–70
 SCID 66, 67–8, 167, 168, 169
 haematuria 172, 174–6
 haemolytic anaemia
 alloantibodies causing 305
 autoimmune *see* autoimmune haemolytic anaemia
 haemolytic disease of the newborn (HDN) 142, 330
 haemolytic transfusion reactions 310
 Haemophilus influenzae type b (Hib)
 meningitis 150, 313
 vaccine 150, 150, **151**
 hairy cell leukaemia 128, **128**
 haptens 4
 Hashimoto's thyroiditis 292–3
 hay fever 92, 93–4
 heart-lung transplantation **165**, 166
 heart transplantation 165, 165–6, 260
 heavy chains, immunoglobulin 8, 8–9
 Helicobacter pylori infection 128, **269**
 helminth infections 52–3, 254
 helper T cells 24–5
 antigen-mediated activation 25
 antigen recognition 6
 hemidesmosomes 226
 Henoch–Schönlein nephritis (purpura) 176, 177, 177, 230
 hepatitis
 acute fulminant 280
 autoimmune 283–4, **284**
 chronic active *see* chronic active hepatitis
 chronic persistent 280, 283
 seronegative 283
 viral 277–83
 hepatitis A 277–8, **278**, 279
 antibody response 277, 278
 vaccine 152, 277–8
 hepatitis B **278**, 278–81, 279
 acute infection 279, 279–80
 carriers 279–80, 280
 chronic 280, 280
 complications 42, 215, 280
 reducing neonatal risks 328
 therapy 153, 280–1
 vaccine 281
 hepatitis C **278**, 281–2
 bystander damage 42
 cryoglobulinaemia 231
 natural history 281, 281
 persistence 41
 therapy 153, 282
 transmission 281, 311
 hepatitis D (delta) virus 282
 hepatitis E **278**, 282–3
 hepatitis G virus 283

hepatocellular carcinoma 280
 Herceptin (trastuzumab) 147, 156
 hereditary angioedema (HAE) 228–9, 229
 hereditary periodic fevers 217–18, 218
 herpes gestationis 227
 herpes labialis (cold sores) 220, 221
 herpes simplex virus (HSV)
 conjunctivitis 238–9
 latency 41
 stromal keratitis 241
 type 1 (HSV-1) 39
 type 2 (HSV-2) 39, 40
 herpes viruses 38, 39
 immune evasion mechanisms 41
 herpes zoster (shingles) 41, 128
 highly active antiretroviral therapy (HAART)
 82–3
 histiocytes 36
 histocompatibility antigens 158
 histocompatibility genetics 158
 histocompatibility testing 350
Histoplasma capsulatum 49
 HIV infection/AIDS 40, 77–84
 breastfeeding 327
 clinical spectrum 78–9, 79
 diagnosis 82, 349
 gastrointestinal involvement 267, 267
 immunopathogenesis 79–82
 immunosuppressive effect 40
 mycobacterial infections 46, 47
 neurological complications 313–14, 314
 persistent generalized lymphadenopathy 80
 respiratory tract infections 248,
 249
 skin manifestations 220–1, 222
 therapeutic options 82, 82–4
 transmission 78
 tuberculosis co-infection 46, 250
 HIV (AIDS)-related dementia 78, 314
 HIV vaccines 83–4
 HLA (human leucocyte antigens) 6, 158
 see also MHC
 HLA associations
 anti-GBM disease 184
 autoimmune disease 116
 coeliac disease 271
 insulin-dependent diabetes mellitus 295
 rheumatoid arthritis 200, 200
 seronegative spondyloarthritides 202, 203
 systemic sclerosis 235
 HLA-B27 110, 202, 203, 242
 HLA haplotypes 158, 159, 159
 HLA matching
 haematopoietic stem cell transplantation 158, 167
 renal allograft survival and 163,
 163–4
 renal transplantation 158, 159
 HLA typing 350
 Hodgkin's disease 129, 129–30
 hormones
 antibodies to 330–1
 replacement therapy 120
 triggering autoimmune disease
 116–17
 house dust mites 96, 97, 102
 Howell–Jolly bodies 272, 272
 HSCT *see* haematopoietic stem cell
 transplantation
 human chorionic gonadotrophin antibodies
 330–1
 human herpes virus type 6 (HHV-6) 39
 human herpes virus type 7 (HHV-7) 39

human herpes virus type 8 (HHV-8) 39, 40
 human immunodeficiency virus infection *see*
 HIV infection/AIDS
 human leucocyte antigens *see* HLA
 human mucosal lymphocyte antigen 1 (HML-1)
 264
 human normal immunoglobulin 152
 human papillomaviruses (HPV)
 oncogenicity 40, 40
 skin cancer and 220
 vaccine 151, 152
 human-specific immunoglobulins 152–3
 human stem cell transplantation *see*
 haematopoietic stem cell transplantation
 human T-cell leukaemia virus (HTLV-1) 40,
 128
 HuMax-CD4 145
 humidifier lung 255, 255
Humira (adalimumab) 145, 204, 206
 humoral immunity 2, 27–8, 37
 hydralazine 118
 hygiene hypothesis 52, 89
 hyperacute rejection 161
 hyper-eosinophilic syndrome 254
 hyper IgD syndrome 218
 hyper-IgE syndrome (HIES) 74, 74–5
 autosomal dominant (AD-HIES) 49–50,
 74–5
 hyper-IgM syndrome 60–2
 pure B-cell forms 62
 X-linked 60–1
 hypersensitivity 30, 87
 autoimmune diseases 118, 119
 drug 90, 92, 117, 287, 287
 Gell and Coombs classification 30, 32
 laboratory tests 342–4
 parasitic infections 53
 type I *see* immediate hypersensitivity
 type II (cell-bound antigen) 30, 31, 32, 53
 type III (immune complex) 30, 31, 32, 53
 type IV *see* delayed-type hypersensitivity
 hypersensitivity pneumonitis *see* extrinsic allergic
 alveolitis
 hyperthyroidism 290–2
 hyperviscosity 136, 335
 hypogammaglobulinaemia
 of infancy 57–8, 327
 of prematurity 327
 hypopyon 241, 241
 hyposensitization therapy 90, 92, 93–4
 hypothyroidism 293, 293–4
 IA-2 antibodies 295
 I antigen, cold antibodies 304
 ibritumomab tiuxetan (Zevalin) 147
 idiopathic interstitial pneumonias (IIP) 256–8,
 257
 idiopathic pulmonary fibrosis (IPF) 256, 256,
 257–8
 idiopathic thrombocytopenic purpura *see*
 immune thrombocytopenia
 idiotypic determinants 9
 IgA 9, 11–12
 breast milk 327
 common variable immunodeficiency
 62
 dimeric structure 9
 Fc receptors (FcR) 15
 functions 28
 gastrointestinal immunity 264
 plus IgG subclass deficiencies 62, 64
 secretory 264, 266
 selective deficiency 62–5, 65, 273–4
 IgA nephropathy 174–6, 176
 IgD 9, 12
 IgE 9, 12
 antigen-specific antibody tests 343, 344
 atopic eczema 102–3
 Fc receptors (FcR) 15
 functions 28
 helminth infections 52, 52
 immediate (type I) hypersensitivity 29, 30,
 87–8, 88
 induction of inflammation 29
 respiratory tract 246
 total serum 344
 IgG 11, 12
 common variable immunodeficiency 62
 complement activation 21–2
 Fc receptors (FcR) 15
 functions 28–9
 oligoclonal bands 315, 316, 337, 337
 placental transfer 107, 325–7
 subclass deficiencies 62, 64
 subclasses and functions 9, 11
 transient low levels in infancy 57, 57–8
 IgG4-related disease (IgG4-RD) 107–8
 IgG index, cerebrospinal fluid (CSF) 337, 337
 IgM 9, 11, 12
 complement activation 21–2
 functions 28
 paraproteins 133, 136
 pentameric structure 9
 ignorance, immunological 111
 IκB deficiency 71
 immediate (type I) hypersensitivity 30, 32,
 87–8
 parasitic infections 53
 immune-complex disease
 arthropathy 196
 direct immunofluorescence 339
 investigation 337–9
 pathogenesis in humans 179, 179–80
 immune complexes
 opsonization and transport 21,
 21
 SLE pathogenesis 211, 211
 type III hypersensitivity 30, 31,
 32
 immune-complex (glomerulo)nephritis
 acute 176–7, 177
 chronic 178–80, 179
 experimental 179
 pathogenesis in humans 179, 179–80,
 180
 rapidly progressive 184
 sites of immune complex deposition 179,
 181
 immune exclusion 264
 immune manipulation 137–56
 immune potentiation 138, 153–6
 immune response 2
 adaptive *see* adaptive immune response
 factors affecting 29
 fetal, development 325, 326
 gastrointestinal 265
 genetic regulation 25
 to infection 37, 37
 innate *see* innate immune response
 physiological outcomes 28–9
 regulation 29
 viruses interfering with 40–1, 41
 immune system
 molecules recognized by 4
 organization 30–3
 tissue damage caused by 29–30

- immune thrombocytopenia (ITP) 142, 305–8
 acute (childhood) 305–6, 307, **307**
 alloantibodies causing 306
 autoimmune 305, 306–8
 chronic 307, **307**
 pregnancy in 307–8, 330
 immunization 148–53
see also vaccines
 active 149, **149**
 combined primary T- and B-cell
 immunodeficiencies 67
 contraindications **152**
 HIV infection 82
 passive 149, 152–3
 prior to/during pregnancy 325, 328
 routine **151**, 151–2
 theoretical basis 149–50
 travellers 152
 immunochemical assays 334, 337–8
 immunocompromised host *see*
 immunosuppressed host
 immunodeficiency 54–85
 antimicrobial antibody tests 339,
339
 classification 55, 55
 infections complicating 55, 56
 primary 55–76
 secondary 76–84, **77**
 immunofixation
 M bands **133**, 335, 336
 oligoclonal bands 337, 337
 immunofluorescence *see* direct
 immunofluorescence; indirect
 immunofluorescence
 immunoglobulin(s) 8–10
see also antibodies; IgA; IgE; IgG; IgM
 antigen-binding site 9
 Fc receptors (FcR) 15
 human normal 152
 human-specific 152–3
 intravenous *see* intravenous immunoglobulin
 investigation techniques 333–7
 isotypes (classes) 9, **9**, 11–12
 isotype switching 27, 27–8, 327
 molecular structure 8, 8–9, 9
 monoclonal 28
 monoclonal bands *see* M bands
 qualitative tests 335–7
 quantitative tests 333–5, 337
 serum levels 56, 57
 somatic hypermutation 12
 subcutaneous (SCIG) 66, 152–3
 surface-bound 8, 27
 VDJ gene recombination 10, **10**
 immunoglobulin replacement therapy 142
see also intravenous immunoglobulin
 primary antibody deficiencies 59, 62, 65–6
 immunoglobulin supergene family of adhesion
 molecules 10–11, **11**
 immunohistochemistry 342
 immunolocalization, tumour 147–8
 immunological ignorance 111
 immunological privilege 111, 237
 immunosuppressed host
 autoimmune disease 114
 EBV infection 38
 infections 84, 84–5
 lymphoma risk 141
 Pneumocystis pneumonia 140
 respiratory tract infections 248, 249
 immunosuppression 138–48
 infectious agents inducing 40–1, 51–2, 53, 77
 preventing autoimmunity 113, 114
 immunosuppressive drugs 138–41
 anti-GBM disease 184
 autoimmune complications 114
 idiopathic interstitial pneumonias 258
 infectious complications 77, 140
 lupus nephritis 183
 mechanisms of action 138
 psoriasis 224–5
 renal transplant recipients 160, **161**
 SLE 207
 topical 141
 transplantation 139, 140, 141
 indirect immunofluorescence 339–41, **340**,
340
 antimitochondrial antibodies 285, 285
 autoimmune hepatitis 284
 pernicious anaemia 268
 skin biopsies 227
 infants
see also children; neonates
 HIV infection 78–9
 immunization **151**, **151**
 primary antibody deficiencies 57
 SCID 66
 transient hypogammaglobulinaemia 57,
 57–8, 327
 infections 34–53
 antibody assays 339
 arthritis and 195–7
 blood-borne 310–11, **311**
 breakdown of tolerance 114
 central nervous system 313–14
 conjunctival 238–9, 240
 diabetes pathogenesis 295–6
 factors influencing **35**
 gastrointestinal 267–8
 haematopoietic stem cell transplant recipients
 169
 immunization against 148–53
 immunodeficiencies 55, 56
 immunosuppressed host 84, 84–5
 maternal 325
 mechanical barriers 35
 non-specific defences 35, 35–6
 primary antibody deficiencies 57, 59, 65
 protection of fetus and neonate against
 325–8
 reactive arthritis 203–4
 recurrent at a single site 65
 renal transplant recipients 84, 164, 164–5
 resistance to 35–7
 skin and 220–1
 SLE 210
 specific immune responses 37, 37
 triggering autoimmunity 117
 infectious mononucleosis 37–8
 infective endocarditis 260
 infertility 298
 inflammation 29–30
 asthma 96, 96
 defence against infection 36, 36
 development of autoimmunity 114–15
 granulomatous 250
 role of complement 21, 29
 T-effector cells 26
 inflammatory bowel disease (IBD) 204, 275–7,
 317
 inflammatory muscle disease 217
 infliximab **145**, 202
 Crohn's disease 276
 psoriasis 225
 sarcoidosis 252
 influenza A virus 41, 247
 innate immune response 2, **3**, 17–24
 effector molecules **11**
 molecules recognized 4
 primary defects 70–6, **72**
 recognition molecules 4–6
 insertional mutagenesis 123, 154
 in situ hybridization 348
 insulin antibodies 295
 insulin-dependent diabetes mellitus (IDDM)
294, 294–7
 coeliac disease association 299
 genetic factors **115**, **116**, 295
 immunopathogenesis 294–6, 295
 pancreatic transplantation 166, 296
 role of immunological tests 296–7,
 297
 treatment 296
 integrins **15**, **16**
 interdigitating dendritic cells 18, 19
 interferon(s) **153**, **153**
 SLE pathogenesis 210
 interferon- α (IFN- α) **13**
 therapy 153, 282
 interferon- β (IFN- β) therapy 153, 317
 interferon- γ (IFN- γ) **13**, 47
 protozoal infections 51
 therapy 153
 interferon gamma release assay (IGRA) 251,
 345–6
 interleukin(s) **12**
 interleukin-1 (IL-1) **12**, **13**
 interleukin-1 receptor antagonist, recombinant
 202, 206
 interleukin-1 receptor-associated kinase (IRAK)-4
 deficiency 6, 70–1
 interleukin-1 (IL-1) receptors, primary defects
 70
 interleukin-2 (IL-2) **12**, **14**
 therapy 154
 interleukin-4 (IL-4) **14**, 27, 27
 interleukin-5 (IL-5) **13**, **14**
 interleukin-6 (IL-6) **13**
 interleukin-7 (IL-7) receptor deficiency **68**, **69**
 interleukin-8 (IL-8, now CXCL8) **13**,
14
 interleukin-10 (IL-10) **14**, 26
 interleukin-12 (IL-12) **14**, 249
 interleukin-12 (IL-12) receptor deficiency 75
 interleukin-13 (IL-13) **14**
 interleukin-15 (IL-15) **14**
 interleukin-16 (IL-16) **14**
 interleukin-17 (IL-17) **13**, 26, 49–50
 interstitial lung disease 252–8, **253**
 connective tissue diseases 258, **258**
 interstitial pneumonia
 acute **257**
 idiopathic (IIP) 256–8, **257**
 non-specific (NSIP) **257**, 258
 smoking-associated **257**
 intolerance 87
 intraepithelial lymphocytes (IELs) 264–5, 266
 intraocular inflammation 242
 intravenous immunoglobulin (IVIG)
 growth-restricted neonates 325–7
 Guillain-Barré syndrome 321
 immune thrombocytopenia 307
 Kawasaki's disease 142, 143
 non-specific immunomodulation 142, **142**
 passive immunization 152–3
 primary antibody deficiencies 65–6
 intrinsic factor (IF) 270
 antibodies 270, **270**, 271
 invariant chain, MHC class II 8, 8

IPEX syndrome 27, 110, 116, 298–9
 ipilimumab 145, 156
 IRAK-4 deficiency 6, 70–1
 ischaemic heart disease (IHD) 201, 210
see also myocardial infarction
 islet-cell antibodies (ICAs) 294, 295, 295,
 296–7, 340
 isoelectric focusing 337, 337
 isotypes, immunoglobulin 9, 9,
 11–12
 isotype switching 27, 27–8, 327
 itch-scratch cycle 103
 IVIG *see* intravenous immunoglobulin
 Jak 3 kinase deficiency 68, 69
 J chain 9, 12
 Jo-1 antibodies 217, 343
 joint disease 195–206
factors in assessment 195
inflammatory 195, 195
patterns 195
 juvenile idiopathic arthritis (JIA) 205, 205–6,
 243
 Kaposi's sarcoma 78, 79, 81
 kappa (κ) light chains 9
 Kawasaki's disease 143, 260, 261
intravenous immunoglobulin therapy 142,
 143
 keratic precipitates 242, 242
 keratinocytes 220, 221, 224
 keratitis 239, 241
 keratoconjunctivitis sicca 241
 kidney disease 171–93
clinical syndromes 172–3
immunological mechanisms 172
multiple myeloma 135
 kidney transplantation *see* renal transplantation
 killing, target cell 28
 Kupffer cells 36
 La (SS-B) antibodies 208, 213, 343
 laboratory tests 333, 334
 lambda (λ) light chains 9
 Lambert-Eaton myasthenic syndrome (LEMS)
 312, 313, 320, 322
 lamina propria lymphocytes 265,
 266
 lamivudine 280–1
 Langerhans cells 18, 220
 latent state, virus infection 41
 late-phase response (LPR) 88
 latex rubber allergy 90, 90, 91
 leishmaniasis 51, 51, 52
 lens-induced uveitis 243
 leprosy 26, 46, 48, 48
 leucocyte adhesion deficiency 74
 leucocyte–endothelial interactions 15–16, 16
 leukaemia 122–8
see also specific types
 acute 123–6, 125
 cells of origin 124, 127
 chronic 126–8, 127
 diagnosis 123, 125
 stem cell transplantation 126, 167, 169,
 169–70
 leukotriene receptor antagonists 97
 light chain-associated amyloidosis (AL
 amyloidosis) 136, 189–90, 191
 light chains, immunoglobulin 8, 8, 9
multiple myeloma 135
urine analysis 336–7
 limbal vernal conjunctivitis 93

limbic encephalitis 322
 linear IgA bullous dermatosis 227
 lipids, immune recognition 27
 Listeria monocytogenes
intrauterine infection 325, 326
meningitis 85
 liver and kidney microsome (LKM) antibodies
 283–4
 liver disease 277–87
alcohol-induced 287
autoimmune 283–7
drug-induced 287
viral hepatitis 277–83
 liver transplantation 165, 165
autoimmune liver diseases 284, 286,
 287
viral hepatitis 281, 282
 Loeffler's syndrome 254
 L-selectin 15, 33
 lung disease
connective tissue diseases 258, 258
interstitial 252–8
pulmonary vasculitis 258–9
 lung transplantation 165, 166, 258
 lupus anticoagulant 206, 310
 lupus erythematosus
cutaneous 226, 231–2, 233
discoid (DLE) 110, 231–2, 233
subacute cutaneous (SCLE) 232, 232, 233
systemic *see* systemic lupus erythematosus
 lupus nephritis 183, 183
 Lyme disease 196, 260
 lymphatic network 33
 lymph nodes 20, 33
 lymphocytes
see also B cells; T cell(s)
adaptive immunity 24, 24
assessment methods 344–6
atypical 38, 128
breast milk 327
cross-matching, renal transplantation 159,
 160
development 3, 30–2
functional tests 345–6, 347
gastrointestinal tract 264–5, 266, 267
gene rearrangement studies 349
intraepithelial (IELs) 264–5, 266
lamina propria 265, 266
pulmonary 246
quantification of subsets 345, 345, 346, 347
recirculation pathways 33, 33
transformation 345
lymphocytic organizing pneumonia 257
lymphoid cells
development 30–2
tumours of *see* lymphoma
lymphoid organs
primary 33
secondary 33
lymphoma 122, 128–31
AIDS-related 78
cold haemagglutinin disease 304
EBV-induced 141
immunopathogenesis 128–9, 129
secondary immunodeficiency 77
lymphoproliferative diseases 121–36
cells of origin 124
diagnostic techniques 122
EBV-induced 38
post-transplant (PTLD) 141, 164–5
primary antibody deficiencies 65
secondary immunodeficiency 77
X-linked (XLP) 27, 38

ysis
complement-mediated 20, 22
molecules inducing 13
T-cell mediated 26

macrophage colony-stimulating factor (M-CSF)
 14
 macrophages 17
see also monocytes
alveolar 246
as antigen-presenting cells 18
defence against infection 36, 36
differentiation 3, 17
functional defects 70–1, 74
granuloma formation 249, 249
mycobacterial infections 47, 47–8
protozoal infections 51, 52
receptors and functions 17, 18
 MAG (myelin-associated glycoprotein) antibodies
 322
 major histocompatibility complex *see* MHC
 malaria 50–1, 51, 152
 malignant disease
see also cancer; tumour cells
biological treatments 153, 154, 154
coeliac disease-related risk 274
common variable immunodeficiency 65
dermatomyositis association 217
paraneoplastic syndromes 322, 322–3
renal transplant recipients 165
secondary immunodeficiency 77
SLE 210
uses of monoclonal antibodies 147–8
viruses inducing 40, 40
 malnutrition 77
malt workers' lung 255
mannan binding lectin (MBL) 4, 22
 Mantoux test 26, 251, 251
 maraviroc 83
 MASP (MBL-associated serine protease) 22
 mast cells
direct activation 88
IgE-mediated activation 29, 30, 87–8
mediators 87–8, 88
 M bands (monoclonal bands)
densitometric analysis 335, 336
serum protein electrophoresis 335
typing by immunofixation 133, 335, 336
urine tests 337
 M cells (microfold cells) 264, 266
 measles/mumps/rubella (MMR) vaccine 151,
 152
 measles virus 40–1, 314
 melanoma, malignant 155–6
membranoproliferative glomerulonephritis
(MPGN) 180–3
type I 180–1, 181, 182
type II 181, 182, 182–3
membranous glomerulonephritis 188–9
 memory B cells 28
 memory T cells 25
 meningitis 313
meningococcus (Neisseria meningitidis) 196,
 313
 mepolizumab 96, 146
 mesangium 173, 174
 MHC (major histocompatibility complex) 6–8,
 7, 158, 158
see also HLA
antigen presentation 7–8
polymorphism 6
restriction 7, 7
typing 350

- MHC class I 7, 7, 158
 antigen presentation 7–8, 8
 compatibility, in transplantation 158, 159, 160
 cytotoxic T cell responses 26
 inherited deficiency 68
 MHC class II 7, 7, 158
 activation of helper T cells 25
 antigen presentation 8, 8
 compatibility, in transplantation 158, 159, 160
 immunological ignorance 111
 inherited deficiency 68
 MHC class III region 7, 8
 microalbuminuria 172
 microarrays 349–50
 microbial antigens, detection of antibodies to 339
 β_2 -microglobulin (β_2 m) 7, 7
 microscopic polyarteritis (MPA) 215, 259
 minimal-change nephropathy (MCN) 187–8
 minocycline 119
 mixed connective tissue disease (MCTD) 212, 212–13
 molecular mimicry 117, 117
 molecules, key 2–16
 monoarthritis 195
 monoclonal antibodies
 anti-tumour 147–8, 156
 applications 142–8
 chimeric 143
 humanized 142, 143
 lymphocyte analysis 345, 347
 potential targets 144, 144
 production 333–4, 334
 for specific immunomodulation 142–7
 therapeutic 144–7
 transplant recipients 160
 monoclonal bands *see* M bands
 monoclonal gammopathies 322
 monoclonal gammopathy of unknown significance (MGUS) 131–3, 132, 132, 134
 monocyte chemotactic protein (MCP) 14
 monocytes 17
 see also macrophages
 counts 346
 functional defects 70–1
 functional tests 346–7
 monocytopenia 70
 mononuclear phagocytic cells 17, 18
 Muckle Wells syndrome 218
 mucosa-associated lymphoid tissue (MALT) 265
 mucosal immune system 264–5
 multifocal motor neuropathy (MMN) 321–2
 multiple myeloma 133–5
 diagnosis 132, 133, 134, 134–5
 recurrent infections 77, 134
 renal complications 192, 193
 treatment 135
 vs. Waldenström's macroglobulinaemia 135, 136
 multiple sclerosis (MS) 314–18
 aetiology 316, 317
 cerebrospinal fluid tests 315, 315–16
 chronic posterior uveitis 243
 diagnosis 314, 315
 genetic factors 115, 316
 immunopathogenesis 316, 316–17
 treatment 317–18
 treatment-associated Graves' disease 114
 muramyl dipeptide (MDP) 151
 muscle disease, inflammatory 217
 muscle-specific tyrosine kinase (MuSK)
 antibodies 319
 myalgic encephalitis (ME) 42
 myasthenia gravis 108, 318–20
 early-onset (EOMG) 318–19, 319
 evidence for autoimmunity 106, 319
 heterogeneity 318–19, 319
 neonatal 108, 319
 mycobacterial infections 45–8
 bystander damage 48
 immune evasion mechanisms 47–8, 48
 increased susceptibility 74
 normal immune response 47, 47
 Mycobacterium avium-intracellulare (MAC) 46, 47
 Mycobacterium leprae 46, 48
 Mycobacterium tuberculosis 45–6, 47, 48, 250
 see also tuberculosis
 mycophenolate mofetil 139, 160
 mycoses
 subcutaneous 49, 49
 superficial 48–9, 49
 systemic 49, 49, 50
 MyD88 deficiency 6, 71
 myeloma
 multiple *see* multiple myeloma
 smouldering (asymptomatic) 132
 myeloma kidney 192, 193
 myocardial infarction 165, 210, 261
 myocarditis 260
 myositis, autoimmune 217, 217, 258
 myxoedema 293–4
 pretibial 292
 natalizumab 145, 314, 317
 natural immunity *see* non-specific immunity
 natural killer (NK) cells 23, 23–4
 development 3
 surface receptors 10, 23, 23
 negative selection 31, 110–11
 neisserial infections, recurrent 76
 Neisseria meningitidis (meningococcus) 196, 313
 NEMO deficiency 71
 neonates
 see also infants
 Graves' disease 291, 330
 IgG status 325–7
 myasthenia gravis 108, 319
 neutropenia 308
 protection against infection 325–8
 thrombocytopenia 306, 307–8, 330
 nephritis
 see also glomerulonephritis; tubulointerstitial nephropathy/nephritis
 acute 172
 acute immune-complex 176–7, 177
 nephrotic syndrome 77, 172, 186–90, 187
 neuroimmunology 312–23
 neuromuscular junction, autoimmune diseases of 318, 318–20
 neuromyelitis optica (NMO) 318, 322
 neuropathies, immune-mediated 320–2, 321
 neutralization, antibody-mediated 28
 neutropenia 70, 71–2
 acute lymphoblastic leukaemia 126
 causes 72, 308, 308
 drug-induced 308
 immune 308
 neutrophils 17
 autoantibodies 308
 counts 346
 defence against infection 36, 36
 functional tests 346–7, 348
 primary functional defects 71–4, 74
 NF κ B pathway defects 70–1
 nickel dermatitis 222
 nitric oxide dismutase 2 (NOD2) 276
 nitroblue tetrazolium (NBT) test 72–4, 347
 NKT cells 24, 24, 25, 27
 NOD2 gene mutations 276
 non-Hodgkin's lymphoma (NHL) 130, 130–1
 non-insulin-dependent diabetes mellitus (NIDDM or type 2 diabetes) 294, 294, 296
 non-specific immunity 35, 35–6
 primary defects 70–6
 Northern blotting 348
 Nramp1 gene 51
 nucleotide analogues (NUCs) 280–1
 nut allergy 99
 occupational asthma 96
 oestrogens 116, 212
 ofatumumab 127, 145
 OKT3 antibodies 145
 oligoarthritis 195
 oligoclonal IgG bands 315, 316, 337, 337
 omalizumab 97, 146
 oncogenes 122
 oncogenic viruses 40, 40
 oophoritis, autoimmune 298
 opportunistic infections 55
 HIV infection 78, 79
 immunosuppressed host 84
 opportunistic mycoses 49
 opsonins 23, 36
 opsonization 20–1, 28–9
 optic neuritis 314
 oral allergy syndrome 99
 oral tolerance 265
 organ-specific autoimmune diseases 106, 289
 endocrine 289, 289–90
 in pregnancy 326, 330
 osteoarthritis 195
 otezolizumab 145
 Ouchterlony method 344
 palivizumab 146
 pancarditis 259
 pancreatic transplantation 165, 166, 296
 pannus 198
 paraneoplastic syndromes 322, 322–3
 paraproteininaemias
 benign 131–3
 differential diagnosis 133
 laboratory techniques 133, 335, 336
 multiple myeloma 134–5
 polyneuropathies 322, 322
 Waldenström's macroglobulinaemia 136
 parasitic infection 50–3, 254
 parathyroid disease 298
 paroxysmal nocturnal haemoglobinuria (PNH) 305
 parvovirus B19 197
 passive immunization 149, 152–3
 patch-testing 221–2
 pathogen-associated molecular patterns (PAMPs) 4, 36
 pattern recognition receptors (PRRs) 4–5, 36
 inherited defects 70
 P-component 190

peanut allergy 98–9
 pegylated interferon- α (PEG-IFN- α) 153, 282
 pemphigoid 226
 bullous 227, 227
 cicatrizing conjunctivitis 238
 pemphigoid gestationis 227
 pemphigus foliaceus 227
 pemphigus vulgaris 225, 226, 226–7
 D-penicillamine 118, 319
 penicillin allergy 90
 pentraxins 211–12
 perennial allergic rhinitis 93, 94
 perennial (vernal) conjunctivitis 93, 238
 perforin 13
 pericarditis 259–60
 periodic fevers, hereditary 217–18, 218
 peripheral corneal melting syndrome 241
 peripheral neuropathies
 autoimmune 320, 320–2, 321
 chronic inflammatory 321–2
 peripheral tolerance 111–13, 112
 mechanisms of breakdown 114–15
 pernicious anaemia (PA) 116, 268–70, 269, 270
 pertussis 151–2
 Peyer's patches 264, 266
 phagocytic cells 17
 defence against infection 35–6, 36
 functional tests 346–7
 phagocytosis 23, 36, 347
 Philadelphia chromosome 122, 123
 photopheresis 148
 PIG-A gene mutations 305
 pigeon breeders' disease 255
 pimecrolimus, topical 103–4, 141
 pirfenidone 258
 pituitary disease 298
 placental transfer, IgG 107, 325–7
 plasma cell dyscrasias 131–6
 plasma cells 28
 plasmacytoid dendritic cells 19
 plasma exchange 148
 plasmapheresis 148, 149
 Waldenström's macroglobulinaemia 136
 plasma products 311
 platelet antibodies 307, 330
 platelet transfusions 311
 pneumococcal infections 247
 overwhelming post-splenectomy 77, 152
 pneumococcal vaccines 151, 152, 247, 328
 Pneumocystis jirovecii pneumonia 49, 78, 79, 140
 pneumonia 246
 bacterial 247
 cryptogenic organizing 257
 idiopathic eosinophilic 254, 254
 immunocompromised host 248
 interstitial *see* interstitial pneumonia
 lymphocytic organizing 257
 pneumonic eosinophilia 254
 podocytes 173, 173–4
 polio vaccine 151, 265
 polyarteritis nodosa (PAN) 213–15, 215, 230–1
 polyarthritis 195
 polyclonal antibodies 141–2, 334, 335
 polymerase chain reaction (PCR) 339, 349, 349
 polymorphonuclear leucocytes *see* neutrophils
 polymyalgia rheumatica (PMR) 215–16
 polymyositis 217
 polysaccharide capsular antigens 42–3, 44, 62
 positive selection 31, 110

post-infectious glomerulonephritis 177–8
 post-myocardial injury syndromes 260
 post-partum thyroiditis 293
 post-streptococcal glomerulonephritis (PSGN) 45, 45, 177–8, 178, 179
 post-transplant lymphoproliferative disorder (PTLD) 141, 164–5
 post-viral fatigue syndrome 42
 precipitating antibodies, detection 344, 344
 pre-eclampsia 329
 pregnancy 324–31
 disorders of 328–30
 in immune thrombocytopenia 307–8, 330
 maternal infection 325
 organ-specific autoimmune diseases 326, 330
 SLE 328, 329, 329
 premature infants, transient
 hypogammaglobulinaemia 57–8, 327
 premunition 53
 pretibial myxoedema 292
 primary antibody deficiencies (PADs) 55–66
 complications 65
 diagnosis 55–6, 57, 58
 differential diagnosis 65
 genetic forms 55
 management 65–6
 presenting infections 57, 59, 65
 prevalence 56
 selective or partial 62–5
 types 57, 57–65
 primary biliary cirrhosis (PBC) 106, 284, 284–6
 clinical and laboratory features 284–5, 285
 histological features 285, 286
 primary lymphoid organs 33
 primary sclerosing cholangitis (PSC) 286–7
 programmed cell death *see* apoptosis
 progressive multifocal leucoencephalopathy 314
 progressive systemic sclerosis *see* systemic sclerosis
 prolactin 116–17
 properdin deficiency 76
 protease inhibitors, HIV 83
 proteases, bacterial 44
 protectin (CD59) 16
 protein(s)
 electrophoresis 335, 335
 quantitative assays 334–5
 protein-losing enteropathy 77
 proteinuria 172, 186
 proto-oncogenes 122, 123
 protozoal infection 50–2
 psoriasis 224–5
 guttate 224, 224
 management 224–5, 225
 pathogenesis 223, 224
 psoriatic arthritis 204, 205
 pulmonary eosinophilia 253–4, 254
 pulmonary fibrosis 253
 causes 253
 helminth infections 254
 idiopathic (IPF) 256, 256, 257–8
 rheumatoid arthritis 201
 systemic sclerosis 232, 235
 pulmonary haemorrhage 184, 259
 pulmonary hypertension
 isolated 258, 258
 systemic sclerosis 232
 pulmonary vasculitis 258–9
 purine nucleoside phosphorylase deficiency 69
 pus, formation of 36
 pyogenic arthritis 196
 pyogenic infections, recurrent 58
 pyrin 217, 218
 qualitative assays 333
 quality assurance (QA) 333
 quality control 333
 quantitative assays 333
 radial immunodiffusion (RID) 334–5
 radioimmunoassay (RIA) 341, 341–2, 342
 RAG1/RAG2 gene mutations 10, 68, 69
 RAG1/RAG2 recombinases 6, 10
 ranibizumab 147
 RANTES 14
 rapamycin (sirolimus) 141, 160, 166
 rapidly progressive glomerulonephritis (RPGN) 184, 184–6
 RAST (radioallergosorbent technique) test 343, 344
 Raynaud's phenomenon 232, 234, 234
 reactive arthritis (arthritis urethritis) 197, 202, 203–4, 241
 receptor editing 114
 receptors
 for effector molecules 13–15
 non-antigen-specific 4
 recognition molecules 4–10
 recognition phase, immune response 2
 recombinant DNA technology 347–50
 recombination 10, 10
 recurrent spontaneous abortion (RSA) 328–9
 regulatory T cells (Tregs) 24, 25, 26, 27
 allergic disease 89
 induced (iTregs) 26
 natural 26
 peripheral tolerance 113, 114
 Reiter's syndrome *see* reactive arthritis
 relapsing fever 44
 relapsing polychondritis 204
 relative serum viscosity (RSV) 335
 renal failure 172
 renal transplantation 158–65
 causes of graft failure 160
 clinical rejection 161, 161–2
 complications 141, 164–5
 disease recurrence after 165, 193, 193
 graft survival 163–4
 IgA nephropathy 176
 immunopathology of rejection 162–3
 immunosuppressive therapy 160, 161
 pattern of infection 84, 164, 164–5
 recipient and donor selection 159, 159, 160
 tissue matching 158, 159
 renal tubular acidosis 192
 respiratory burst, assessment 347
 respiratory diseases 246–59
 see also lung disease; pneumonia
 allergic 93–7
 granulomatous 248–52, 249
 respiratory tract, defence mechanisms 246
 respiratory tract infections 246–8, 247
 immunocompetent host 247
 immunocompromised host 248, 249
 recurrent or severe 248, 248
 restriction fragment length polymorphisms (RFLP) 349
 reticular dysgenesis 68
 retinal vasculitis 243, 243
 retinitis 239, 243
 retroviruses 79–80
 reverse transcriptase inhibitors 82–3
 rhesus compatibility, blood transfusion 310

- rhesus incompatibility 142, 330
 rheumatic fever 44–5, 45, 260
 rheumatic heart disease 45
 rheumatoid arthritis (RA) 197–202
 aetiology 200, 200–1
 childhood 206
 diagnosis 106, 197
 differential diagnosis 207, 209
 extra-articular features 197
 genetic factors 115, 116
 immunopathogenesis 198–200, 199, 199
 lung disease 258, 258
 management 144, 201–2
 outcome 201, 201
 pathology 196, 198
 pregnancy and 329
 septic arthritis 196
 serology 197
 rheumatoid factor 106, 197
 rhinitis
 allergic 93–4, 94
 causes 93
 medicamentosa 93
 non-allergic (vasomotor) 93
 ribavirin 153, 282
 ribonucleoprotein (RNP) antibodies 208, 213, 343
 rituximab 145
 autoimmune haemolytic anaemia 303
 granulomatosis with polyangiitis 259
 immune thrombocytopenia 307
 lymphoid malignancies 127, 131, 136, 156
 multiple sclerosis 317
 SLE 207
 Ro (SS-A) antibodies 208, 213, 232, 343
 rodent handlers' lung 255
 rubella vaccine 151
 ruplizumab 145
Salmonella typhi 44
 SAP gene mutations 38
 sarcoidosis 251–2
 eye involvement 238, 241, 243
 systemic involvement 252
 scavenger mechanisms 112
 Schirmer test 213, 214
 schistosomiasis 51, 52–3
 Scl-70 autoantibodies 233, 343
 scleritis 239, 241
 scleroderma *see* systemic sclerosis
 sclerosing cholangitis 286–7
 seasonal allergic conjunctivitis 92–3, 238
 seasonal allergic rhinitis 93–4
 secondary lymphoid organs 33
 secretory IgA 264, 266
 secretory piece (secretory component) 9, 11, 264
 selectins 15, 16
 selective IgA deficiency 62–5, 65, 273–4
 self-antigens *see* autoantigens
 self-tolerance *see* tolerance
 sensitivity test 333, 334
 sensorimotor neuropathy, paraneoplastic 322
 sensory neuropathy, paraneoplastic 322
 septic arthritis 196, 196–7
 seronegative spondyloarthritis 202–5, 242
 serum amyloid A (SAA) 190
 serum amyloid P (SAP) 190, 211–12
 serum analysis
 antimicrobial antibodies 339, 339
 autoantibodies 339–42
 immunoglobulins 333–6, 335, 336
 serum sickness 30, 31
 one-shot 176–7, 177
 vasculitis skin rash 229
 severe combined immune deficiency (SCID)
 66–70, 69
 gene therapy 68–70, 154, 155
 stem cell transplantation 66, 67–8, 167, 168, 169
 variants 68
 Sézary syndrome (SS) 128, 128
 shingles (herpes zoster) 41, 128
 sickle-cell disease 50–1
 sirolimus *see* rapamycin
 Sjögren's syndrome 213, 213, 214, 241
 pregnancy in 329
 primary biliary cirrhosis 286
 skin 220
 antibodies 340
 granulomas 220
 infections and 220–1
 skin-associated lymphoid tissue (SALT) 220
 skin cancer 220
 skin diseases 219–35
 allergic 100–4
 autoimmune 225–8
 systemic disease-associated 228–35
 T-cell-mediated 221–5
 skin grafting, allogeneic 166
 skin-prick tests 88, 90
 SLAM (signalling lymphocyte activation molecule) 38
 SLE *see* systemic lupus erythematosus
 sleeping sickness 51
 Sm (Smith) antibodies 208, 343
 smoking, cigarette 246, 257
 smoking-associated interstitial pneumonia 257
 smooth-muscle antibodies (SMA) 283, 284, 340
 somatic hypermutation 12
 Southern blotting 348, 348, 350
 specificity, test 333, 334
 sperm antibodies 298, 331
 spleen 20, 33
 splenectomy
 autoimmune haemolytic anaemia 304
 immune thrombocytopenia 307
 infection susceptibility after 77, 152
 spontaneous abortion, recurrent 328–9
Sporotrichium schenckii 49
 staphylococcal keratitis 241
Staphylococcus aureus infections 102
 STAT1 gene mutations 49
 STAT2 gene mutations 49–50, 74–5
 stem cell factor (SCF) 33
 stem cell transplantation *see* haematopoietic stem cell transplantation
 steroid cell antibodies 298
 steroids *see* corticosteroids
 Stevens–Johnson syndrome 238, 239–40
 stiff man syndrome 295, 320
 Still's disease, adult-onset 206
 streptococcal antigens 43
 streptococcal infections
 complications 44–5, 45
 normal immune response 43
 streptococcal toxic shock syndrome 44
 Streptococcus pneumoniae (pneumococcus)
 antibodies 339, 339
 infections *see* pneumococcal infections
 vaccines *see* pneumococcal vaccines
 stroke, in young patients 309
 subacute cutaneous lupus erythematosus (SCLE) 232, 232, 233
 subacute sclerosing panencephalitis (SSPE) 314
 subacute thyroiditis 293
 subcutaneous immunoglobulin (SCIG) 66, 152–3
 superantigens 4
 associated diseases 44
 bacteria as 43, 43
 sympathetic ophthalmia 243–4
 synovial lining 195
 synovitis 195
 systemic lupus erythematosus (SLE) 110, 206–12
 aetiology and pathogenesis 210–12, 211
 antiphospholipid antibodies 206, 207, 208, 309
 cerebral 323, 323
 clinical features 206, 206–7
 coagulation factor antibodies 309–10
 complement deficiency 75
 diagnostic criteria 207, 207
 differential diagnosis 207, 209
 drug-induced 117, 119, 207
 genetic factors 115, 210–11
 laboratory findings 207, 208, 209, 341
 Listeria monocytogenes meningitis 85
 lung disease 258
 management 207–9, 210
 myocardial infarction risk 261
 neutropenia 308
 pregnancy and 328, 329, 329
 prognosis 209–10
 pulmonary vasculitis 259
 renal disease 183, 183, 192
 ultraviolet radiation and 118, 212
 vs. mixed connective tissue disease 212–13
 vs. other forms of lupus erythematosus 231–2, 233
 systemic sclerosis (scleroderma) 213, 232–5, 233
 autoantibodies 233, 234
 diffuse 232
 limited (CREST syndrome) 232, 233
 lung disease 258
 pathogenesis 234–5, 235
 pregnancy in 329
 tacrolimus 140–1
 topical 103–4, 141
 transplant recipients 160
 Takayasu's arteritis 261, 262
 TAP proteins 8, 8
 Tc cells *see* cytotoxic T cells
 T cell(s) 2, 24
 activation tests 345–6, 347
 antigen presentation to 7–8, 8, 19
 antigen recognition 6–8, 7, 25
 dendritic cell interactions 19
 development 3, 31–3
 effector 25–7
 fetal 325
 gastrointestinal tract 264–5, 267
 granuloma formation 248–50, 249
 help 25
 lamina propria 265
 mediated adaptive immunity 24–7
 mediated skin disease 221–5
 mycobacterial infections 47, 47
 quantification methods 345
 recirculation pathways 33, 33
 selection in thymus 109–11, 111
 skin homing 220
 tolerance, mechanisms 109–13

T-cell activation
co-stimulatory molecules 19, 19
induced by superantigens 43, 43
regulation and suppression 113
T-cell help 25
T-cell receptors (TCRs) 6–8
antigen recognition 6–8, 7
diversity 6
gene rearrangement studies 349, 350
structure 6
VDJ gene recombination 10
T-dependent antigens 4, 42
technetium (^{99m}Tc) sulesomab 148
techniques, clinical immunology 332–50
TeGenero incident 147
TEL-AML1 fusion protein 124
temporal arteritis *see* giant cell arteritis
tenofovir 83
teplizumab 145
Th0 cells 25
Th1 cells 24, 25, 25, 25–6
contact dermatitis 221, 222
inflammatory response 26
tuberculosis 250
Th1 cytokine profile 25, 25–6
mycobacterial infection 47
type IV hypersensitivity 30
Th2 cells 24, 25, 25
asthma 95–6, 96
atopic eczema 102
helminth infections 52
Th2 cytokine profile 25, 25–6
allergic disease 89
asthma 95–6, 96
Th17 cells 24, 25, 26
asthma 94, 96
Candida infections 49–50
rheumatoid arthritis 199
thalidomide 204–5
thiopurine methyl transferase (TPMT) deficiency 139
thiopurines 139, 139
thrombocytopenia 305, 305
causes 305, 306
drug-induced 308
immune (ITP) *see* immune thrombocytopenia
neonatal 306, 307–8, 330
thrombopoietin receptor agonists 307
thymic education 111
thymoma 319, 319, 320
thymus 31–3
changes in myasthenia gravis 319, 319
T-cell selection 31, 109–11, 111
thyroid atrophy, idiopathic 293–4
thyroid disease 290, 290–4, 291, 294
thyroid eye disease 291–2
thyroid growth-stimulating immunoglobulin (TGI) 291
thyroid microsomal antibody 342
thyroid peroxidase antibodies 290, 290
thyroid-stimulating antibodies 290, 291
thyroid-stimulating hormone (TSH) receptor antibodies 290, 291
thyrotoxicosis 290–2
T-independent antigens 4, 28, 42–3
tissue damage
autoimmune responses to 114–15, 115
immune system-mediated 29–30
infections 42, 44–5, 48
mechanisms in autoimmune disease 118–19, 119
tissue transglutaminase (TTG) 271
antibodies 273–4

tissue typing 158, 350
T lymphocytes *see* T cell(s)
TNF *see* tumour necrosis factor
tocilizumab 146, 202, 206
tolerance (self-tolerance) 109–14
B cell 113–14
central mechanisms 109–11
within eye 237
mechanisms of breakdown 114–15
oral 265
peripheral mechanisms 111–13
thymic mechanisms 109–11, 111
Toll-like receptors (TLRs) 4, 5, 36
signalling pathway defects 6, 70–1
signal transduction 5
tonsillitis, acute bacterial 43
total lymphoid irradiation (TLI) 148
toxic shock syndrome 44
toxoplasmosis 51, 52
trachoma 238
tranexamic acid 229
transformation
EBV-infected B cells 38
lymphocyte 345
malignant, haematopoietic cells 122, 123
virus-induced 40
transforming growth factor- β (TGF- β) 14, 110, 234–5
translocations 122, 123, 124
transplantation 157–70
immunosuppressive therapy 139, 140, 141
tissue matching 158, 350
trastuzumab (Herceptin) 147, 156
travellers, immunization 152
Tregs *see* regulatory T cells
Trichophyton rubrum 49
tropical pulmonary eosinophilia 254
trypanosomiasis 51, 51, 52
tryptase, serum 343–4
tuberculin test (Mantoux test) 26, 251, 251
tuberculosis (TB) 45–6, 250–1
anti-TNF therapy reactivating 147
immune response 47
miliary 250, 250–1
prevention 48, 151, 251
pulmonary 250
risk factors 46, 250
treatment 251
tubular basement membrane (TBM) antibodies 192
tubulointerstitial nephropathy/nephritis (TIN) 172, 190–2
acute drug-induced 191–2
mechanisms 175
tumour cells
killing 28
monoclonal antibodies targeting 147–8, 156
tumour necrosis factor (TNF) 13, 13, 113
tumour necrosis factor- α (TNF- α) 110
granuloma formation 249, 249
rheumatoid arthritis 199, 199
tumour necrosis factor (TNF) inhibitors 144–7, 145
adverse effects 118, 144–7
Crohn's disease 276
juvenile idiopathic arthritis 206
psoriasis 225
rheumatoid arthritis 144, 202
sarcoidosis 252
tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) 217–18, 218
tumour suppressor genes 122

type 1 diabetes *see* insulin-dependent diabetes mellitus
type 2 diabetes *see* non-insulin-dependent diabetes mellitus
typhoid vaccine 152
ulcerative colitis 204, 275, 275–7
ultraviolet (UV) radiation
effects on skin 220, 221
psoralens with 148
triggering SLE 118, 212
Ureaplasma infections 65
urine tests, immunoglobulins 336–7
ursodeoxycholic acid (UDCA) 286
urticaria 100, 100–2, 101
acute 101
chronic 101, 104
chronic idiopathic 101
physical 101
urticular vasculitis 101, 230
ustekinumab 146, 225, 317
uveitis 241–4
anterior 239, 242–3
Behcet's disease 241
classification 241–2, 242
experimental allergic (EAU) 242
idiopathic 242
juvenile idiopathic arthritis 205, 206, 243
posterior 239, 243, 243
post-traumatic 243–4
vaccines 149–50
see also immunization
adjuvants 150–1
anti-tumour 155–6
attenuated 149
immunological requirements 151
killed 149, 150, 150
live 149, 150
polypeptide 152
protein-polysaccharide conjugate 150
side effects 151–2
variable (V) regions, immunoglobulin 8, 9
varicella zoster virus (VZV) 39, 41
vasculitis
ANCA-associated 185–6, 187, 230
causes 229–30, 230
classification 230–1, 231
coronary arteries 260
eye involvement 241, 243
pulmonary 258–9
skin involvement 229–31
systemic 213–17
urticular 101, 230
veiled cells 18
vernal conjunctivitis 93, 238
viral infections 37–42
bystander damage 42
cell-mediated immunity 39–40
conjunctiva 238–9
early host response 23, 23
hepatitis 277–83
immune responses 38–40, 40
myocarditis 260
recurrent 37
respiratory tract 247
skin involvement 220–1
T-cell lysis 26
transient arthritis 197
triggering lymphoma 128, 129
virulence 35

viruses
 antigen processing and presentation 7–8, 8
 cell tropism 40
 direct effects 40–1
 immune evasion mechanisms 41,
41
 inducing lymphoid tumours 122
 infecting immune cells 40–1, **41**
 killing of cells 28, 40
 neutralization 39
 oncogenic 40, **40**
 persistence 41
 specific immune responses 37, 37
 visilizumab **145**

vitamin B₁₂ deficiency 268, 270,
271
 vitamin D 249, 250
 vitiligo 228
 VLA-4 **15**
 Vogt–Koyanagi syndrome 243, 244
 vulvo-vaginitis, acute 49
 Waldenström's macroglobulinaemia 135–6,
136
 warm antibody haemolytic anaemias **301**,
 301–4
 wasp venom anaphylaxis 91
 weal and flare reaction 30, 88

Wegener's granulomatosis *see* granulomatosis with
 polyangiitis
 whooping cough 151–2
 Wiskott–Aldrich syndrome 66, **69**
 X-linked agammaglobulinaemia (XLA) 58–9,
59
 X-linked lymphoproliferative disease (XLP) 27,
 38
 zanolimumab **145**
 Zevalin (ibritumomab tiuxetan) 147
 zidovudine 82–3
 ZnT8 antibodies 295

